Neuromuscular Blocking Drugs Market Trends

Growth Drivers

Rising Surgical Treatments

According to the United Nations Department of Economics and Social Affairs, there are currently 703 million people aged 65 or older, a number which is expected to grow to 1.5 billion by 2050.

Increasing life expectancies in different countries across the world has led to significant growth in the older populations. Countries such as Japan and China contain a higher number of the elderly population due to improved healthcare, political, economic and social conditions. Consequently, complexity of surgical treatment has increased along with the demand for neuromuscular blocking drugs. Owing to the rise in chronic diseases, the acceptance of surgical treatments by medical professionals has further increased. This is predicted to propel the demand for neurological blocking drugs and boost the market growth during the forecast period.

Increasing Research and Development Activities

Increasing investment in neuromuscular blocking drugs research and development to invent sophisticated technology that helps in enhancing the drug performance would help drive the market growth during the forecast period. Safety of the consumer remains the first priority of both the drug makers and medical professionals. Upon development of new classes and combinations of drugs which would have minimum side effects, their safety and efficacy would be enhanced which is estimated to drive the market growth further. neuromuscular blocking drugs market is anticipated to grow exponentially during the forecast period.

Challenge

High Cost of Drug and Ill-Effects

High cost associated with the surgical treatment and neuromuscular blocking drugs is predicted to adversely affect the growth of the market over the forecast period. Some of the side effects of neuromuscular blocking drugs include dysrhythmia, muscle pain, hyperkalemia, cardiac arrest and prolonged paralysis among others. Hence, it is estimated to hamper the neuromuscular blocking drugs market growth during the forecast period. The stringent regulatory environment associated with the negative side effects of the drug are further predicted to hinder the market growth.